Life
Briefing: Asthma patients suffered as GSK pursued ‘egregious’ price hikes, senator says
Strategic angle: Families report financial and treatment struggles after GSK's price increases on asthma inhalers.
editorial-staff
1 min read
Updated 25 days ago
GSK has replaced a widely used asthma inhaler with a higher-priced alternative, raising concerns about patient access to essential medications.
Families have reported facing substantial financial challenges due to these price increases, which have made treatment less affordable.
The implications of these changes extend beyond individual patients, potentially affecting overall healthcare system efficiency and patient outcomes.